Novo Nordisk Up, Vestas Surges, Babcock Rises

On this episode of Stock Movers:
- Novo Nordisk A/S shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a serious form of liver disease, beating rival Eli Lilly & Co. to the US market. The stock gained as much as 5% in early trading in Copenhagen.
- Vestas Wind Systems A/S shares rose sharply after guidance issued by the Treasury Department and IRS on tax credits related to clean energy projects was deemed by analysts to be far less onerous than feared. The stock gained as much as 13%, hitting the highest level since November.
- Babcock was up as much as 2.8% following RBC adding the firm to its UK defence coverage, starting with an outperform rating, as it sees a strong outlook for the support services firm based on “an attractive hopper of opportunities” both at home and abroad.

See omnystudio.com/listener for privacy information.